14 DEC 2005

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 724 6/6/53 4S
Express Mail Label Number

20. Other items or information:

Form PTO-1390-MOD U. S. Department of Commerce Patent and Trademark Office (REV 10-96)		ATTORNEY'S DOCKET NUMBER ON/4-33220A								
TRANSMITTAL LETTER TO T	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)									
DESIGNATED/ELECTED O	10/560751									
CONCERNING A FILING UN										
INTERNATIONAL APPLICATION NO. PCT/EP2004/006794	INTERNATIONAL FILING DATE 23 June 2004 (23.06.04)	PRIORITY DATE CLAIMED 24 June 2003 (24.06.03)								
TITLE OF INVENTION										
PHARMACEUTICAL COMPOSITION COMPRISING CYCLIC SOMATOSTATIN ANALOGUES										
APPLICANT(S) FOR DO/EO/US LAMBERT ET AL.										
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:										
Applicant herewith submits to the Onited States Designated/Elected Onice (DO/EO/OS) the following items and other information.										
1. This is a FIRST submission of items cond										
 This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay 										
examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority										
date. 5. A copy of the International Application as	date.									
a. is transmitted herewith (required only if not transmitted by the International Bureau). b. has been transmitted by the International Bureau. (See Form PCT/IB/308)										
c. is not required, as the application	c. is not required, as the application was filed in the United States Receiving Office (RO/US).									
7. Amendments to the claims of the Interna	tional Application under PCT Article 19									
b. have been transmitted by the Inte										
	 c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 									
A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).										
0. 🔲 A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C.										
371(c)(5)).										
Items 11. to 16. below concern document(s) or information included.										
11. An Information Disclosure Statement und	ier 37 CFR 1.97 and 1.98.									
12. An assignment document for recording.	2. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.									
13. A FIRST preliminary amendment.										
☐ A SECOND or SUBSEQUENT prelimina										
14. An Application Data Sheet under 37 CFF	. 🛛 An Application Data Sheet under 37 CFR 1.76.									
15. A substitute specification.	A substitute specification.									
16. A change of power of attorney and/or ad	☐ A change of power of attorney and/or address letter.									
17. A computer-readable form of the sequen	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.									
18. A second copy of the published Internation	A second copy of the published International Application under 35 U.S.C. 154(d)(4).									
19. A second copy of the English language to	A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).									

U.S. APPLICATION NO (II LOGWITY See 37 CFR)	PPLICATION NO. (ILLUSWITY SEG-37 CFRH.) POTTERNATIONAL APPLICATION NO. PCT/EP2004/006794			ATTORNEY'S DOCKET NUMBER ON/4-33220A					
The following fees are submitted:							CALCUL	ATIO	NS PTO USE
21. Basic national fee		• • • • • • • • • • • • • • • • • • • •				\$300			
22. Examination Fee If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)						-			
. ⊠ All other situations									
23. Search fee If Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$ If International Search Report was prepared and provided to the Office \$400 All other situations									
TOTAL OF 21, 22 AND 23 =					\$	900			
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.									
Total Sheets Extra sheets			Iditional 50 or from the distribution of the d		F	RATE			
- 100 = /50 :					X \$	250	\$		
Surcharge of \$130 for furnishing the oath of declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).					\$				
	BER FILE		UMBER EXTRA			TE FO	•		
Total claims 10 Independent claims 3		20 =	0	$\frac{x}{x}$	\$ \$	50 	\$ \$		
MULTIPLE DEPENDENT CLAIM			-	+	\$	360	\$		
TOTAL OF ABOVE CALCULATIONS =					\$	900			
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).					\$				
SUBTOTAL =					\$	900			
Processing fee of \$130 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).					 				
			Т	OTAL N	ATION	IAL FEE =	\$	900	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +					\$				
TOTAL FEES ENCLOSED =					\$	900			
							Amou be: refu		\$
		-					cha	rged	\$
a. A check in the amount of \$ to cover the above fees is enclosed.									
b. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$900 to cover the above fees. A duplicate copy of this form is enclosed.									
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.									
Send all correspondence to the address associated with Customer No. 001095, which is currently: Value Customer Cus									
Novartis Corporate Intellectual Pro One Health Plaza, Buildir East Hanover, NJ 07936-	ng 104			Lydia T. M Attorney f Reg. No. (862) 778	or Appli 36,214		Š	_	_